Related Experiment Videos
Insights
Combination therapy with Noliprel (Perindopril/Indapamide) effectively lowers blood pressure in essential hypertension patients. This study highlights its positive impact on cardiac remodeling and safety profile.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Monotherapy for essential hypertension often yields suboptimal results.
- Combination antihypertensive therapy offers potential for synergism and reduced adverse effects.
- Essential hypertension management requires effective and safe treatment strategies.
Purpose of the Study:
- To evaluate the efficacy and safety of low-dose Noliprel (Perindopril/Indapamide) in treating essential hypertension.
- To investigate the impact of Noliprel on echocardiographic parameters and cardiac hemodynamics.
- To assess the influence on myocardial remodeling processes.
Main Methods:
- A 3-month prospective study involving 30 treatment-naive essential hypertension patients.
- Prescription of low-dose Noliprel (2.00 mg Perindopril/0.625 mg Indapamide).
- Detailed echocardiographic assessment including left ventricular myocardium mass index and wall thickness.
Main Results:
- Noliprel demonstrated significant antihypertensive activity, achieving target blood pressure in 83.3% of patients within one month.
- An additional 16.7% of patients required a dosage increase to achieve target blood pressure after 3 months.
- Positive trends in echocardiographic parameters and cardiac hemodynamics were observed during therapy.
Conclusions:
- Low-dose Noliprel is a highly effective and safe antihypertensive medication.
- Noliprel positively influences myocardial remodeling processes.
- The combination therapy is metabolically neutral with no observed side effects.
Abstract:
Monotherapy prevailing nowadays in the treatment of essential hypertension is one of the causes of not sufficiently effective hypotensive therapy. Combination of antihypertensive drugs is a more efficient strategy as synergism of applied medications may be reached and not high doses may develop less adverse effects. 30 patients (17 men and 13 women, average age is 51 years) with hypertension which have not taken antihypertensive drugs from different reasons have been prescribed Noliprel being a combination of Perindopril and Indapamid in low doses (2.00 mg and 0.625 mg accordingly) for 3 months. The study conducted by the author differs from the trials on Noliprel effectiveness by its more profound investigation of the echocardiography parameters and cardial hemodynamics. The measurement of left ventricular myocardium mass index, wall and interventricular septal thickness and many other echocardiographic parameters have been studied. Noliprel has already demonstrated good antihypertensive activity in 83.3% of patients after one month therapy. 16.7% of patient increased dose intake to two pills per day and after 3 months of the therapy their arterial pressure reached the target level. The author considered in details the dynamics of echocardiography parameters during therapy with Noliprel. Noliprel is a highly effective and safe medication which positively influences on processes of myocardium remodeling and is metabolically neutral. No side effects have been seen during the treatment with this medication by the patients having been treated.
Related Concept Videos
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
Antihypertensive Drugs: Vasodilators
Adrenergic Antagonists: ɑ and β-Receptor Blockers
Heart Failure V: Medical Management
Antihypertensive Drugs: Types of β-Blockers
Heart Failure Drugs: β-Blockers